1.Synchronization isolation method for multiple types of cells from mouse liver.
Jian GAN ; Cui Feng JI ; Xiao Rong MAO ; Jiang Tao WANG ; Chun Yan LYU ; Yi Fan SHI ; Yao LIAO ; Ya Li HE ; Lian SHU ; Long LI ; Jun Feng LI
Chinese Journal of Hepatology 2023;31(5):532-537
		                        		
		                        			
		                        			Objective: To explore a simple and feasible method for the isolation and purification of hepatocytes, hepatic stellate cells (HSC), and lymphocytes from mice. Methods: The cell suspension was obtained from male C57bl/6 mice by hepatic perfusion through the portal vein digestion method and then isolated and purified by discontinuous Percoll gradient centrifugation. Trypan blue exclusion was used to determine cell viability. Glycogen staining, cytokeratin 18, and transmission electron microscopy were used to identify hepatic cells. Immunofluorescence was used to detect α-smooth muscle actin combined with desmin in HSCs. Flow cytometry was used to analyze lymphocyte subsets in the liver. Results: After isolation and purification, about 2.7×10(7) hepatocytes, 5.7×10(5) HSCS, and 4.6×106 hepatic mononuclear cells were obtained from the liver of mice with a body weight of about 22g. The cell survival rate in each group was > 95%. Hepatocytes were apparent in glycogen deposited purple-red granules and cytokeratin 18. Electron microscopy showed that there were abundant organelles in hepatocytes and tight junctions between cells. HSC had expressed α-smooth muscle actin and desmin. Flow cytometry showed hepatic mononuclear cells, including lymphocyte subsets such as CD4, CD8, NKs, and NKTs. Conclusion: The hepatic perfusion through the portal vein digestion method can isolate multiple primary cells from the liver of mice at once and has the features of simplicity and efficiency.
		                        		
		                        		
		                        		
		                        			Male
		                        			;
		                        		
		                        			Mice
		                        			;
		                        		
		                        			Animals
		                        			;
		                        		
		                        			Keratin-18
		                        			;
		                        		
		                        			Actins
		                        			;
		                        		
		                        			Desmin
		                        			;
		                        		
		                        			Liver
		                        			;
		                        		
		                        			Hepatocytes
		                        			;
		                        		
		                        			Hepatic Stellate Cells
		                        			
		                        		
		                        	
3.Risk Factors Analysis of Thromboembolism in Patients with Lymphoma Chemotherapy.
Xiao LI ; Shu-Ling HOU ; Xi LI ; Li LI ; Ke LIAN ; Ju-Ya CUI ; Gang-Gang WANG ; Tao YANG
Journal of Experimental Hematology 2022;30(1):131-135
		                        		
		                        			OBJECTIVE:
		                        			To evaluate the risk factors affecting thromboembolism in lymphoma patients with chemotherapy.
		                        		
		                        			METHODS:
		                        			Three hundred and four consecutive lymphoma patients treated by chemotherapy between January 2012 and July 2019 were enrolled and retrospectively analyzed, consisting of 111 patients with thromboembolism and 193 without thromboembolism. Univariate analysis was used to compare the clinical characteristics and related laboratory examination between the patients, while multivariate Logistic regression analysis were used to identify the risk factors affecting thromboembolism in lymphoma patients with chemotherapy.
		                        		
		                        			RESULTS:
		                        			Univariate analysis showed that the female, BMI <18.5 or >24, ≥60 years old, with abnormal platelets before chemotherapy, prolonged single hospitalization days and patients at Ann Arbor stage III and IV could increase the incidence of thromboembolism in lymphoma patients treated by chemotherapy. Multivariate Logistic regression analysis showed that abnormal platelet count before chemotherapy, patients at Ann Arbor stage III and IV, and female were all the independent risk factors affecting thromboembolism in lymphoma patients thromboembolism after chemotherapy (P<0.05).
		                        		
		                        			CONCLUSION
		                        			For lymphoma chemotherapy patients, female, abnormal platelet count before chemotherapy and Ann Arbor stages III and IV show a significantly higher risk for thromboembolism. Thus, preventive anticoagulation therapy is recommended.
		                        		
		                        		
		                        		
		                        			Antineoplastic Combined Chemotherapy Protocols
		                        			;
		                        		
		                        			Female
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Lymphoma/drug therapy*
		                        			;
		                        		
		                        			Middle Aged
		                        			;
		                        		
		                        			Prognosis
		                        			;
		                        		
		                        			Retrospective Studies
		                        			;
		                        		
		                        			Risk Factors
		                        			;
		                        		
		                        			Thromboembolism/epidemiology*
		                        			
		                        		
		                        	
4.Clinical practice guidelines for multigene assays in patients with early-stage breast cancer: Chinese Society of Breast Surgery (CSBrS) practice guidelines 2021.
Jiu-Jun ZHU ; De-Chuang JIAO ; Min YAN ; Xu-Hui GUO ; Ya-Jie ZHAO ; Xiu-Chun CHEN ; Cheng-Zheng WANG ; Zhen-Duo LU ; Lian-Fang LI ; Shu-De CUI ; Zhen-Zhen LIU
Chinese Medical Journal 2021;134(19):2269-2271
5.Clinical practice guidelines for modified radical mastectomy of breast cancer: Chinese Society of Breast Surgery (CSBrs) practice guidelines 2021.
De-Chuang JIAO ; Jiu-Jun ZHU ; Li QIN ; Xu-Hui GUO ; Ya-Jie ZHAO ; Xiu-Chun CHEN ; Cheng-Zheng WANG ; Zhen-Duo LU ; Lian-Fang LI ; Shu-De CUI ; Zhen-Zhen LIU
Chinese Medical Journal 2021;134(8):895-897
		                				6.Identification of different Bupleurum  varieties based on carbohydrate-specific chromatograms
		                			
		                			Li-xia SHI ; Ke LI ; Xue-mei QIN ; Zhen-yu LI ; Lian-jie CUI ; Shu-ying LI ; Yu-xin CAO ; Sheng-jin WANG
Acta Pharmaceutica Sinica 2020;55(12):2968-2975
		                        		
		                        			
		                        			 Characterization of the polysaccharides and monosaccharides of 
		                        		
		                        	
7.Clinical Value of Serum Amyloid A and Misfolded Transthyretin for Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients.
Hu LIU ; Shu-Ling HOU ; Shu-Ying LIU ; Xi LI ; Li LI ; Ju-Ya CUI ; Ke LIAN ; Xiao-Bo WU ; Gang-Gang WANG ; Qiao-Hua ZHANG
Journal of Experimental Hematology 2020;28(6):1923-1932
		                        		
		                        			OBJECTIVE:
		                        			To evaluate the clinical value of serum amyloid A (SAA1/2) and misfolded transthyretin (TTR) for relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) patients.
		                        		
		                        			METHODS:
		                        			30 R/R DLBCL patients were enrolled as observation group, 20 remission/stabilization DLBCL and 10 chronic lymphadenitis patients were enrolled as control group. SELDI technique, Tris-Tricine sodium dodecyl sulfate-polyacrylamide gel electro-phoresis, the shotgun-LTQ-MS method, and bioinformatics technique were used to detected and analyzed SAA and TTR in R/R DLBCL patients. SPSS 21.0 software was used to analyze the relationship between the high expression of SAA, misfolded TTR in serum and the clinicopathological features, survival time of R/R DLBCL. patients Chi-square test was used to analyze clinical count data, Kaplan-Meier curve was used for survival analysis, and Log-Rank test was used to compare single-factor survival differences.
		                        		
		                        			RESULTS:
		                        			The high expression of SAA and TTR (SAA
		                        		
		                        			CONCLUSION
		                        			Both SAA and misfolded TTR are poor prognosis factors of R/R DLBCL patients.
		                        		
		                        		
		                        		
		                        			Antineoplastic Combined Chemotherapy Protocols
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Lymphoma, Large B-Cell, Diffuse/drug therapy*
		                        			;
		                        		
		                        			Patients
		                        			;
		                        		
		                        			Prealbumin/therapeutic use*
		                        			;
		                        		
		                        			Prognosis
		                        			;
		                        		
		                        			Serum Amyloid A Protein
		                        			
		                        		
		                        	
8.Expert consensus statement on Kangfu Xiaoyan Suppository in treatment of pelvic inflammatory in clinical practice.
Lian-Xin WANG ; Li-Hui HOU ; Yan-Ming XIE ; Kun MA ; Su-Lun SUN ; Zhe JIN ; Hui-Lan DU ; Dong-Mei WANG ; Hong ZHAO ; Yan-Feng LIU ; Ling TANG ; Kuan-Yong SHU ; Cui-Zhen ZHANG ; Wei SHI ; Si-Yan ZHAN ; Jian-Ping LIU ; Wei CHEN ; Yao-Long CHEN
China Journal of Chinese Materia Medica 2019;44(20):4350-4353
		                        		
		                        			
		                        			Kangfu Xiaoyan Suppository is widely used in the treatment of gynecological inflammatory diseases. Long-term clinical application and a certain amount of research evidences show that Kangfu Xiaoyan Suppository can alleviate the clinical symptoms of pelvic inflammatory diseases,reduce the recurrence rate,and relieve sequelae,with a better safety and economic characteristics. As a type of nationally protected traditional Chinese medicine and type B medicine included in medical insurance,it has been selected as a Chinese patent medicine for rectal administration. It was included in the Guidelines for diagnosis and treatment of common gynecological diseases of traditional Chinese medicine published by the Chinese Academy of Traditional Chinese Medicine in 2012,the Pelvic inflammatory diseases diagnosis and treatment guidelines issued by the Infectious Diseases Collaborative Group of the Obstetrics and Gynecology Branch of the Chinese Medical Association in 2014,and the group standard of Single use of traditional Chinese medicine/combined antibiot guidelines for clinical practice-pelvic inflammatory diseases of the Chinese Academy of Traditional Chinese Medicine in 2017. To further enhance clinicians' understanding of the drug and better guide its rational clinical use,experts from the field of gynecology of traditional Chinese and Western medicine were invited to develop and compile this expert consensus. This consensus takes full account of clinical evidences and expert clinical experience,and form recommendations for clinical problems based on evidences and consensus recommendations for clinical problems without evidence by nominal grouping method. The expert consensus is mainly formed in the consideration of six factors: quality of evidence,economy,efficacy,adverse reactions,patient acceptability and others. Based on clinical research evidences and expert experience,this consensus provides a preliminary reference for the clinical use of the drug in a concise and clear format. However,evidence-based support is still required in a large number of high-quality studies,and this consensus will be revised in the future according to new clinical problems and the update of evidence-based evidence in practical application.
		                        		
		                        		
		                        		
		                        			Consensus
		                        			;
		                        		
		                        			Drugs, Chinese Herbal/therapeutic use*
		                        			;
		                        		
		                        			Female
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Medicine, Chinese Traditional
		                        			;
		                        		
		                        			Nonprescription Drugs
		                        			;
		                        		
		                        			Pelvic Inflammatory Disease/drug therapy*
		                        			;
		                        		
		                        			Suppositories
		                        			
		                        		
		                        	
9.Clinical Observation of Acupuncture plus Medication in Treating Chronic Pelvic Inflammatory Disease
Shao-Yang CUI ; Shuang-Shuang YUAN ; Chao-Jian TAN ; Ren-Da YANG ; Lian-Qiang FANG ; Wen-Jun MA ; Ming-Zhu XU ; Xin-Sheng LAI ; Shu-Hui WANG
Shanghai Journal of Acupuncture and Moxibustion 2018;37(2):196-199
		                        		
		                        			
		                        			Objective To observe the clinical efficacy of acupuncture plus medication in treating chronic pelvic inflammatory disease. Method By using the random number table, sixty-eight patients with chronic pelvic inflammatory disease were randomized into an acupuncture-medication group of 34 cases and a medication group of 34 cases. The clinical efficacies were compared after 2 courses of treatment, and the symptoms and body signs scores and syndrome score of traditional Chinese medicine (TCM) were also compared. Result There was a significant difference in comparing the therapeutic efficacy between the acupuncture-medication group and the medication group (P<0.05). After the treatment, the symptoms and body signs scores and TCM syndrome score dropped significantly in both groups (P<0.05), indicating that the two groups both had improvement in the symptoms, body signs and TCM syndrome; there were significant between-group differences in comparing the score differences in the symptoms and body signs scores and TCM syndrome score after the treatment (P<0.05), and the acupuncture-medication group was higher than the medication group. Conclusion Acupuncture plus medication can better ameliorate the symptoms and body signs and TCM syndrome in chronic pelvic inflammatory disease.
		                        		
		                        		
		                        		
		                        	
10.Expressions of microRNA-196a and microRNA-210 in pancreatic cancer and their relationship with survival time
Da-Peng CUI ; Ying-Chun ZHANG ; Jing-Jing LIAN ; Bo LIU ; Fei LIU ; Lei HAN ; Yu-Jia WANG ; Shu-Quan GAO
The Chinese Journal of Clinical Pharmacology 2018;34(7):809-811
		                        		
		                        			
		                        			Objective To analyze the expressions of microRNA-196a (miR-196a) and microRNA-210 (miR-210) in pancreatic cancer and their relationship with the survival time.Methods Twenty-six cases of pancreatic cancer (A group),20 patients with benign pancreatic disease (B group) and 24 healthy subjects (C group) were selected as the subjects.The expressions of miR-196a and miR-210 in the serum of 3 groups of patients were detected by real time fluorescence real time fluorescence quantitative (qRT-PCR) method,and the survival time of the patients with pancreatic cancer was observed.The relationship between the expression of miR-196a and miR-210 in 3 groups,the levels of miR-196a and miR-210 and the survival time of the patients with pancreatic cancer were analyzed.Results The levels of miR-196a expression in A,B and C groups was (1.79 ±0.95),(1.24 ±0.92) and (0.71 ±0.68),respectively,and the miR -210 expression levels were (2.32 ±0.54),(1.25 ±0.36) and (0.98 ±0.22).There were significant differences between A group and B,C groups (all P < 0.05).The half year survival rate of the patients with pancreatic cancer was 61.54%,the 1 year survival rate was 46.15%,and the 2 year survival rate was 3.85%.For patients with pancreatic cancer,the survival time in miR-196a high and low expression groups was(7.58 ± 3.43) and (12.38 ±5.17) months,respectively,in miR-210 high expression group and low expression group was (6.92 ± 3.01) and (10.88 ±4.28) months,the differences were statistically significant (P < 0.05).The sensitivity,specificity and accuracy of miR-196a were 76.92%,93.18% and 70.10%,which of miR-210 68.00%,93.18% and 61.18%,of joint detection 88.46%,95.45% and 83.92%.The indexes obtained by combined detection had statistically significant differences compared with those detected separately (all P < 0.01) Conclusion The expressions of miR-196a and miR-210 are specifically expressed in serum of patients with pancreatic cancer.The combined detection can improve the diagnostic accuracy of pancreatic cancer,and the expression levels of miR-196a and miR-210 are related to the survival time of pancreatic cancer patients.
		                        		
		                        		
		                        		
		                        	
            
Result Analysis
Print
Save
E-mail